Why the study?
Does the arginase inhibitor N ω-hydroxy-nor-L-arginine improve vascular function and lower blood pressure in adult spontaneously hypertensive rats?
Does the arginase inhibitor N ω-hydroxy-nor-L-arginine improve vascular function and lower blood pressure in adult spontaneously hypertensive rats?
In-vivo evidence suggests selective arginase inhibition lowers blood pressure and improves vascular reactivity, highlighting it as a potential new therapeutic strategy for hypertension.
May warrant clinical trials of arginase inhibitors; extends preclinical evidence but leaves human translation open.
Pharmacological inhibition of arginase in adult spontaneously hypertensive rats decreases blood pressure and improves the reactivity of resistance vessels. These data represent in-vivo argument in favor of selective arginase inhibition as a new therapeutic strategy against hypertension.
No takes yet. Share an insight, caveat, or question.
Bagnost et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: